

554,321

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
4 November 2004 (04.11.2004)

PCT

(10) International Publication Number  
**WO 2004/094612 A2**

- (51) International Patent Classification<sup>7</sup>: C12N
- (21) International Application Number:  
PCT/US2004/012568
- (22) International Filing Date: 22 April 2004 (22.04.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/464,350 22 April 2003 (22.04.2003) US
- (71) Applicant (for all designated States except US): A & G  
PHARMACEUTICAL, INC. [US/US]; 9130 Red Branch  
Road, Suite U, Columbia, MD 21045 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): SUN, Le [US/US];  
10239 Threadneedle Ct., Ellicott City, MD 21042, Suite


U/V, Columbia, MD 21045 (US). SERRERO, Glnette  
[US/US]; 10200 Savoy Ct., Ellicott City, MD 21045  
(US). CORVERA, Joe [US/US]; 3729 Yolanda Road,  
Baltimore, MD 21218 (US). HOU, Yodong [US/US];  
3514 Beech Avenue, Apt. F., Baltimore, MD 21211 (US).

(74) Agent: LI, Kening; Crowell & Moring, LLP, Intellectual  
Property Group, P.O. Box 14300, Washington, DC 20044-  
4300 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

[Continued on next page]

(54) Title: CANCER SPECIFIC MONOCLONAL ANTIBODIES



Breast cancer



Bladder cancer



Pancreas cancer

(57) Abstract: Novel monoclonal antibodies and binding fragments thereof  
specific to human breast cancer, lung cancer, colon cancer and other cancers.  
The monoclonal antibody does not bind to the cell surface of normal human  
tissues. The corresponding cancer-specific antigen or antigens with an appar-  
ent molecular weight of 40-52 130-200 kDa and polynucleotides encoding the  
antigen and the CDR regions of the antibody are also disclosed, as well as  
methods for diagnosis, prognosis and treatment of human breast cancer. The  
antibodies have tumor specificity and are useful for therapy, diagnosis, moni-  
toring, detecting and imaging of cancers. The antibody-recognized cancer-spe-  
cific surface antigens can serve as targets for detecting, diagnosing, inhibiting  
or killing cancer cells.



(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*